The present study was to develop solid nanodispersed tablet formulation containing 4 mg of glimepiride for the treatment of Type II diabetes mellitus. Solid nanodispersions of glimepiride (GMP) were prepared using two different ratios of two different carriers and by adopting two different techniques. Solid nanodispersed tablets of glimepiride were prepared by compression of the prepared solid nanodispersions using direct compression method. The differential scanning calorimetry (DSC) analysis and Fourier transform infra-red (FTIR) analysis was conducted for the thermal behavior and surface structure characterization, respectively. The prepared solid nanodispersion and solid nanodispersed tablet were evaluated in terms of pre-compression and post-compression parameters, respectively. The DSC and FTIR studies revealed that there was no interaction between GMP and all the excipients. The resulted values of pre-compression evaluated parameters revealed that the prepared solid nanodispersions powder blends showed poor to excellent flow properties and with drug content ranged from 97.2±0.4% to 99.40.2%, with particle size ranged from 111.2±1.7 nm to 282.5±2.6 nm and with zeta potential ranged from -9.34±38.6 mV to -63.4±12.8 mV. The results of TEM analysis of formula (F6) showed spherically-shaped particles with particle size ranged from 650 nm to 850 nm. The resulted spectra of PXRD analysis of formula (F6) showed much reduced crystallinity of the homogenized form on comparison with pure GMP powder and with un-homogenized form of the same formula. The aqueous phase solubility study showed that, the increase in aqueous solubility was in the range of 2.4 folds for formula (F4) to 7.7 folds for formula (F6). The in-vitro dissolution studies of the prepared solid nanodispersions showed that, formulae F2 and F6 were released the highest quantity of drug. One way ANOVA for the percent of drug released from the prepared GMP-nanodispersion formulae (F1-F8) after 60 and 120 minutes showed significant differences between the percent of drug released from different GMP-nanodispersion formulae, (P<0.05). The disintegration time of the prepared nanodispersed tablets ranged from 140±18 seconds to 235 ±12 seconds. The drug content was be in the ranged of 99.9±0.2% for F8 to 96.9±0.7% for F4 and the weight variation indicated that, none of the tablets deviated from the average weight by more than ±1.5%.
Loading....